Malaria, Falciparum Clinical Trial
— BlueACTnOfficial title:
Safety of Artesunate-amodiaquine Combined With Methylene Blue or Primaquine for Falciparum Malaria Treatment in African Children: A Randomised Controlled Trial
NCT number | NCT02851108 |
Other study ID # | UniHD008 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | October 2016 |
Est. completion date | February 2017 |
Verified date | March 2020 |
Source | Heidelberg University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Safety of artesunate-amodiaquine combined with methylene blue or primaquine for falciparum
malaria treatment in African children: A randomised controlled trial
Elimination has become the goal of malaria programmes in an increasing number of endemic
countries and regions. As resistance against artemisinin compounds has recently started to
emerge in South-East Asia, there is a clear need to develop alternative malaria drug
combinations. Adding another anti-malarial with a short half-life such as methylene blue to
standard ACT (artemisinin-based combination therapy) could be a strategy to prevent
artemisinin resistance development. Moreover, adding a gametocytocidal drug to ACT reduces
the probability of transmission of P. falciparum parasites including drug-resistant
parasites.
Objectives: The primary objective of this trial is to investigate the safety of artesunate
(AS) - amodiaquine (AQ) - methylene blue (MB) compared to AS - AQ - primaquine (PQ) in young
children with uncomplicated falciparum malaria in Burkina Faso.
Status | Completed |
Enrollment | 100 |
Est. completion date | February 2017 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 59 Months |
Eligibility |
Inclusion Criteria: - Weight = 6 kg - Uncomplicated malaria caused by P. falciparum - Asexual parasites = 2 000/µl and = 100 000/µl - Axillary temperature = 37.5°C or a history of fever during the last 24 hours - Burkinabe nationality - Permanent residence in the study area with no intention of leaving during the surveillance period - Written informed consent of parents or care takers Exclusion Criteria: - Severe malaria - Mixed malaria infection - Vomiting (>2 times within 24 hours before the visit) - Any apparent significant disease, including severe malnutrition - A history of a previous, significant adverse reaction or known allergy to one or more of the study drugs - Anaemia (haemoglobin < 7 g/dl) - Treated in the same trial before - All modern antimalarial treatment prior to inclusion (last seven days) - Therapy with serotonin reuptake inhibitors (e.g. citalopram, escitalopram, fluoxetine, Paroxetine, Sertraline) - Simultaneous participation in another investigational study - Patients with known HIV/AIDS disease - Therapy with drugs known to inhibit the liver enzymes cytochrome 2A6 (e.g. methoxsalen, pilocarpine, tranylcypromine) and/or cytochrome 2C8 (e.g. trimethoprim, ketoconazole, ritonavir, saquinavir, lopinavir, gemfibrozil, montelukast) |
Country | Name | City | State |
---|---|---|---|
Burkina Faso | CRSN | Nouna |
Lead Sponsor | Collaborator |
---|---|
Heidelberg University | Centre de Recherche en Sante de Nouna, Burkina Faso |
Burkina Faso,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Haemoglobin Compared to the Baseline | Haemoglobin concentrations will be measured in the field using a HemoCue® (HemoCue® AB, Angelholm, Sweden) | 7 days | |
Secondary | Gametocyte Prevalence | measured microscopically at baseline and on day 1, 2, 3, 7, 14, and 28 of follow-up | 28 days | |
Secondary | Adverse Events (AE) | Reports of observed or self-reported adverse event | 28 days | |
Secondary | Mothers/Caretakers Questionnaire on Acceptance | Acceptance of the different treatment regimens by mothers/caretakers | 14 days | |
Secondary | Gametocyte Density | measured microscopically at baseline and on day 1, 2, 3, 7, 14, and 28 of follow-up | 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02329301 -
Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia
|
N/A | |
Recruiting |
NCT01944189 -
Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics
|
Phase 4 | |
Completed |
NCT01325974 -
Time to Become Negative of Three Rapid Diagnostic Tests for Malaria
|
N/A | |
Terminated |
NCT01442168 -
Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria
|
Phase 1/Phase 2 | |
Terminated |
NCT00374205 -
Randomized Trial on Effectiveness of ACTs in Ghana
|
Phase 4 | |
Completed |
NCT00375128 -
Sporozoite Challenge of Polyprotein Vaccinees
|
Phase 1/Phase 2 | |
Completed |
NCT04609098 -
Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)
|
Phase 2 | |
Terminated |
NCT02281344 -
MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants
|
Phase 1 | |
Completed |
NCT02434952 -
Safety and Tolerability of Low Dose Primaquine
|
Phase 4 | |
Completed |
NCT01213966 -
Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection
|
Phase 2 | |
Completed |
NCT00479206 -
Artemisinin Resistance in Cambodia
|
N/A | |
Completed |
NCT00126906 -
Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi
|
N/A | |
Completed |
NCT01019408 -
Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan
|
Phase 4 | |
Completed |
NCT00529867 -
Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria
|
Phase 4 | |
Completed |
NCT00137553 -
The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children
|
Phase 4 | |
Completed |
NCT02637128 -
In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria
|
Phase 4 | |
Completed |
NCT01222962 -
Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers
|
Phase 1 | |
Unknown status |
NCT00152204 -
The Community Effectiveness of IPTi in Southern Tanzania
|
Phase 3 | |
Terminated |
NCT00084240 -
Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia
|
Phase 2/Phase 3 | |
Completed |
NCT00137514 -
Chloroquine and Amodiaquine for Treatment of Malaria in Children
|
Phase 4 |